


# Care Quality Evaluation (CQE)

Joining the dots ... to better care delivery and evaluation

**Michela Tinelli**

**Contact:**

m.tinelli@lse.ac.uk



## Project profile

### What is your idea

CQE is a digital platform that will empower patients, healthcare professional teams, healthcare managers and healthcare commissioners to better manage, improve, and cost effectively monitor long-term conditions at a population level using individual patient level data. Connecting individual patient outcomes to the economic productivity and social impact of care management on the population suffering from chronic lifelong conditions for the first time, it will realise a multiplication effect at population level from delivering small incremental differences for individual patients.

### What problem are you solving

Life-long chronic conditions have a significant impact on society in general, particularly due to losses in productivity. The global economic impact of the five leading chronic diseases – could reach \$47 trillion in 2030.

There is currently no joined-up mechanism that can support better care delivery for individual patients and simultaneously provide stakeholders responsible for the commissioning, management and delivery of healthcare services with the means to cost-effectively improve quality of care and improve societal productivity at the population level.

### What is your progress to date

Interviews with key stakeholders have validated the market need and the feedback is being used to create a Minimal Viable Product (MVP) – a version of CQE with basic features. The MVP will be trialled and tested with user groups and stakeholders who have already committed to field studies to gain user feedback that will inform further product development in advance of getting the product ready for market

### What resources can help you grow

We have secured funding and a technical partner to build the MVP and identified stakeholders to conduct initial trials and testing. Access to additional stakeholder networks that could contribute to product development, piloting in the field and the identification and creation of new dashboards of indicators with application to other chronic diseases would have a significant impact on growth potential. Further financial investment and the recruitment of a commercial team will be required to take CQE into commercial deployment.

### How will you spend the £50k money

£50K would enable CQE to expand the trialling and testing of the MVP and accelerate the development of CQE to support additional chronic conditions. We have created interest in Europe and the USA in CQE with potential stakeholders who are willing to pilot CQE and help to co-develop the specific indicators that will be required to enable CQE to be used in support of the management of other chronic conditions. This would significantly accelerate the development of a fully commercial product.

### About your team

Dr Michela Tinelli is a qualified pharmacist and senior health economist at the London School of Economics and Political Science, with 15-years' experience in evaluating the benefits and cost-effectiveness of interventions for people with long term conditions. As the founder of CQE, she is currently being supported by the LSE Innovation Office, a junior researcher and a number of external associates.

